In a recent bid TherapeuticsMD Inc. [TXMD] faced a contemporary bid of $1.25 yielding a -4.41% decline where 1.24 million shares have exchanged hands over the last week. TXMD amount got a fall by -3.85% or -$0.05 versus $1.30 at the end of the prior session. This change led market cap to move at 363.26M, putting the price 46.54% below the 52-week high and -57.34% above the 52-week low. The company’s stock has a normal trading capacity of 1.24 million shares while the relative volume is 0.99.
On 13, November 2020, TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock. According to news published on Yahoo Finance, TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 23,437,500 shares of its common stock for net proceeds of approximately $27.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering were sold by TherapeuticsMD.
Analyst Birdseye View:
The most recent analyst activity for TherapeuticsMD Inc. [NASDAQ:TXMD] stock was on May 19, 2020, when it was Downgrade with a Neutral rating from JP Morgan. On December 02, 2019, Guggenheim Initiated a Buy rating. On October 17, 2019, H.C. Wainwright Initiated a Buy rating and increased its price target to $7. On April 30, 2019, Noble Capital Markets Resumed an Outperform rating and increased its price target to $13. On June 15, 2018, JP Morgan Initiated an Overweight rating and boosted its amount on this stock to $11. On September 08, 2017, Morgan Stanley Initiated an Equal-weight rating and boosted its target amount on this stock to $6. Oppenheimer elevated its amount target by recapitulating a higher weight for this stock.
In the past 52 weeks of trading, this stock has oscillated between a low of $0.85 and a peak of $2.93. Right now, the middling Wall Street analyst 12-month amount mark is $7.00. At the most recent market close, shares of TherapeuticsMD Inc. [NASDAQ:TXMD] were valued at $1.25.
TherapeuticsMD Inc. [NASDAQ:TXMD] most recently reported quarterly sales of 19.34 billion, which represented growth of -18.60%. This publicly-traded organization’s revenue is $142,664 per employee, while its income is -$506,164 per employee. This company’s Gross Margin is currently 77.20%, its Pretax Margin is -354.80, and its Net Margin is -354.80. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -73.71, -330.09, -78.47 and -91.77 respectively.
The Principal structure of this organization shows its whole liability to whole principal at 95.71 and the whole liability to whole assets at 77.18. It shows enduring liability to the whole principal at 95.01 and enduring liability to assets at 0.77 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.2733 points at 1st support level, the second support level is making up to 1.2467. But as of 1st resistance point, this stock is sitting at 1.3233 and at 1.3467 for 2nd resistance point.
TherapeuticsMD Inc. [TXMD] reported its earnings at -$0.12 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.14/share signifying the difference of 0.02 and 14.30% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.19 calling estimates for -$0.17/share with the difference of -0.02 depicting the surprise of -11.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for TherapeuticsMD Inc. [NASDAQ:TXMD] is 2.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.03. Now if looking for a valuation of this stock’s amount to sales ratio it’s 12.01 and it’s amount to book ratio is 71.32.
The most recent insider trade was by Finizio Robert G, CEO, and it was the purchase of 46000.0 shares on Jun 09. Collins Cooper C., the Director, completed a purchase of 47500.0 shares on Jun 09. On Jun 08, Collins Cooper C., Director, completed a purchase of 26500.0 shares.